Abbvie Inc. vs Roivant Sciences Ltd.
ABBV vs ROIV — side-by-side comparison from reported financials. ABBV leads 6, ROIV leads 4 of 10 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Roivant Sciences Ltd.
ROIV · Healthcare
$35.44+3.60%Strong
| Metric | ABBV | ROIV |
|---|---|---|
| Price | $276.43 | $35.44 |
| Market cap | $488B | $25.6B |
| Revenue (TTM) | $64.4B | $16.9M |
| Revenue growth | +1.8% | -48.7% |
| Net margin | 9.8% | -7594.2% |
| Free cash flow | $18.2B | -$1.89B |
| Net cash (debt) | ($56.2B) | $3.73B |
| 1-year price return | +19.8% | +119.9% |
| P/E | 77.4 | — |
| P/E vs own history (cheap-side %) | 23% | 73% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | -6% |
| Altman Z-score | 2.33 | 40.50 |
| CV checks passed | 9 of 11 | 5 of 11 |
| Employees | 57,000 | 721 |
Full résumé-style profiles: ABBV CV · ROIV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.